ALDEYRA THERAPEUTICS INC (ALDX) Stock Price, Quote, News and Overview
NASDAQ:ALDX - Nasdaq - US01438T1060 - Common Stock - Currency: USD
ALDX Quote, Performance and Key Statistics
2.16
+0.15 (+7.46%)
The current stock price of ALDX is 2.16 USD. In the past month the price increased by 11.34%. In the past year, price decreased by -42.71%.
ALDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.07 | 328.29B | ||
| AMGN | AMGEN INC | 13.1 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 12.68 | 122.21B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 110.44B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.13B | ||
| ARGX | ARGENX SE - ADR | 299.54 | 34.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.61B | ||
| ONC | BEIGENE LTD-ADR | 5.88 | 25.43B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.78B | ||
| NTRA | NATERA INC | N/A | 22.10B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.31B | ||
| BIIB | BIOGEN INC | 7.48 | 17.35B |
Related stock screener links
About ALDX
Company Profile
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Company Info
ALDEYRA THERAPEUTICS INC
131 Hartwell Avenue, Suite 320
Lexington MASSACHUSETTS 02421 US
CEO: Todd C. Brady
Employees: 9
Phone: 17817614904
ALDEYRA THERAPEUTICS INC / ALDX FAQ
What is the stock price of ALDEYRA THERAPEUTICS INC today?
The current stock price of ALDX is 2.16 USD. The price increased by 7.46% in the last trading session.
What is the ticker symbol for ALDEYRA THERAPEUTICS INC stock?
The exchange symbol of ALDEYRA THERAPEUTICS INC is ALDX and it is listed on the Nasdaq exchange.
On which exchange is ALDX stock listed?
ALDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALDEYRA THERAPEUTICS INC stock?
13 analysts have analysed ALDX and the average price target is 8.45 USD. This implies a price increase of 291.27% is expected in the next year compared to the current price of 2.16. Check the ALDEYRA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALDEYRA THERAPEUTICS INC worth?
ALDEYRA THERAPEUTICS INC (ALDX) has a market capitalization of 129.38M USD. This makes ALDX a Micro Cap stock.
How many employees does ALDEYRA THERAPEUTICS INC have?
ALDEYRA THERAPEUTICS INC (ALDX) currently has 9 employees.
What are the support and resistance levels for ALDEYRA THERAPEUTICS INC (ALDX) stock?
ALDEYRA THERAPEUTICS INC (ALDX) has a support level at 2 and a resistance level at 2.35. Check the full technical report for a detailed analysis of ALDX support and resistance levels.
Should I buy ALDEYRA THERAPEUTICS INC (ALDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALDX, evaluating the profitability, health, valuation and growth aspects
- ALDEYRA THERAPEUTICS INC (ALDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALDEYRA THERAPEUTICS INC (ALDX) Sales and EPS estimates to see what analysts future expectations are.
- ALDEYRA THERAPEUTICS INC (ALDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALDEYRA THERAPEUTICS INC (ALDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALDEYRA THERAPEUTICS INC (ALDX) Stock Chart to make your own analysis
- ALDEYRA THERAPEUTICS INC (ALDX) Latest news and press-releases to stay up to date.
Does ALDEYRA THERAPEUTICS INC (ALDX) stock pay dividends?
ALDX does not pay a dividend.
When does ALDEYRA THERAPEUTICS INC (ALDX) report earnings?
ALDEYRA THERAPEUTICS INC (ALDX) will report earnings on 2025-07-30.
What is the Price/Earnings (PE) ratio of ALDEYRA THERAPEUTICS INC (ALDX)?
ALDEYRA THERAPEUTICS INC (ALDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
What is the Short Interest ratio of ALDEYRA THERAPEUTICS INC (ALDX) stock?
The outstanding short interest for ALDEYRA THERAPEUTICS INC (ALDX) is 8.07% of its float. Check the ownership tab for more information on the ALDX short interest.
ALDX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALDX. When comparing the yearly performance of all stocks, ALDX is a bad performer in the overall market: 94.68% of all stocks are doing better.
ALDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALDX. Both the profitability and financial health of ALDX have multiple concerns.
ALDX Financial Highlights
Over the last trailing twelve months ALDX reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS decreased by -46.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.39% | ||
| ROE | -78.66% | ||
| Debt/Equity | 0.21 |
ALDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to ALDX. The Buy consensus is the average rating of analysts ratings from 13 analysts.